$1.09
-0.01 (-0.91%)
Open$1.11
Previous Close$1.10
Day High$1.12
Day Low$1.08
52W High$2.95
52W Low$0.70
Volume—
Avg Volume75.5K
Market Cap5.76M
P/E Ratio—
EPS$-5.14
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+1,834.9% upside
Current
$1.09
$1.09
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.37M | 557.3K | 516.3K |
| Net Income | -202,299,699 | 76.7K | 85.4K |
| Profit Margin | -1,132.4% | 13.8% | 16.5% |
| EBITDA | -149,478,834 | 122.1K | 108.8K |
| Free Cash Flow | — | 55.8K | 59.0K |
| Rev Growth | +166.9% | +2.4% | +15.9% |
| Debt/Equity | 0.21 | 0.52 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |